Effectiveness of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide from Rilpivirine or Other Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based Antiretroviral Therapy in Virologically Suppressed People with HIV: A Retrospective Analysis (DRIVE-SWITCH Study)
Infectious Diseases and Therapy · 2026-05 · 15 (5) · 1565-1575
DOI: 10.1007/s40121-026-01330-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Infectious Diseases and Therapy, online erschienen am 19.03.2026. Verfasst von Roberta Gagliardini und 17 weiteren Autor:innen. Beteiligte Einrichtung: National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome, Italy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Gilead Sciences.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome, Italy.
- National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome, Italy. alessandro.caioli@gmail.com.
- Gilead Sciences Srl, Milan, Italy.
Förderung
- Gilead Sciences
Zitieren
APA
Gagliardini, R., Caioli, A., Fusto, M., Ottou, S., Forbici, F., Fabeni, L., Maggi, F., Plazzi, M. M., De Zottis, F., Bellagamba, R., Paulicelli, J., Mastrorosa, I., Grilli, E., Pinnetti, C., Mazzotta, V., Caldera, R., Forcina, G., & Antinori, A. (2026). Effectiveness of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide from Rilpivirine or Other Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based Antiretroviral Therapy in Virologically Suppressed People with HIV: A Retrospective Analysis (DRIVE-SWITCH Study). Infectious Diseases and Therapy, 15(5), 1565-1575. https://doi.org/10.1007/s40121-026-01330-7
Vancouver
Gagliardini R, Caioli A, Fusto M, Ottou S, Forbici F, Fabeni L, et al. Effectiveness of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide from Rilpivirine or Other Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based Antiretroviral Therapy in Virologically Suppressed People with HIV: A Retrospective Analysis (DRIVE-SWITCH Study). Infectious Diseases and Therapy. 2026;15(5):1565-1575. doi:10.1007/s40121-026-01330-7
BibTeX
@article{Gagliardini2026,
author = {Gagliardini, Roberta and Caioli, Alessandro and Fusto, Marisa and Ottou, Sandrine and Forbici, Federica and Fabeni, Lavinia and Maggi, Fabrizio and Plazzi, Maria Maddalena and De Zottis, Federico and Bellagamba, Rita and Paulicelli, Jessica and Mastrorosa, Ilaria and Grilli, Elisabetta and Pinnetti, Carmela and Mazzotta, Valentina and Caldera, Roberto and Forcina, Gabriele and Antinori, Andrea},
title = {Effectiveness of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide from Rilpivirine or Other Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based Antiretroviral Therapy in Virologically Suppressed People with HIV: A Retrospective Analysis (DRIVE-SWITCH Study)},
journal = {Infectious Diseases and Therapy},
year = {2026},
volume = {15},
number = {5},
pages = {1565--1575},
doi = {10.1007/s40121-026-01330-7}
}
EUVIMED